Suchergebnisse - (Person:"Kim, Jin Yong")

PubPharm (6)

1

Safety and Effectiveness of Regdanvimab for COVID-19 Treatment : A Phase 4 Post-marketing Surveillance Study Conducted in South Korea

enthalten in: Infectious diseases and therapy | 2023

von Lee, J. | Bu, S. | Song, E. | +14

2

Safety and Effectiveness of Regdanvimab for COVID-19 Treatment: A Phase 4 Post-marketing Surveillance Study Conducted in South Korea

enthalten in: Infectious diseases and therapy | 2023

von Lee, J. | Bu, S. | Song, E. | +14

3

Regdanvimab for patients with mild-to-moderate COVID-19 : a retrospective cohort study and subgroup analysis of patients with the Delta variant

enthalten in: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases | 2023

von Jang, Y. | Oh, Y. | Kim, J.

4

A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019

enthalten in: Open forum infectious diseases | 2022

von Kim, J. | Săndulescu, O. | Preotescu, L. | +21

ErratumIn: Open Forum Infect Dis. 2023 Apr 19;10(4):ofad196. - PMID 37089779

5

Clinical Effectiveness of Regdanvimab Treatment for Mild-to-Moderate COVID-19 : A Retrospective Cohort Study

enthalten in: Current therapeutic research, clinical and experimental | 2022

von Jang, Y. | Oh, Y. | Kim, J.

6

Safety, Virologic Efficacy, and Pharmacokinetics of CT-P59, a Neutralizing Monoclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Protein : Two Randomized, Placebo-Controlled, Phase I Studies in Healthy Individuals and Patients With Mild SARS-CoV-2 Infection

enthalten in: Clinical therapeutics | 2021

von Kim, J. | Jang, Y. | Hong, J. | +16

1
[1]